Evidence map›Paper›PMID 41305346›Full record

SynthesisPathogens (Basel, Switzerland)2025

Whole Genome Sequencing and Comparative Genomics of the Emerging Pathogen

Judit Henczkó, Ákos Tóth, Márta Knausz, Béla Gartner, Ákos Reményi, Edit Bíró, Erzsébet Létay, László Rókusz, Szilárd Tóth, Bernadett Pályi and 5 more

Abstract readCase ReportsSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Judit HenczkóDepartment of National Biosafety Laboratory, National Center for Public Health and Pharmacy, H-1097 Budapest, Hungary.
Ákos TóthDepartment of Bacteriology, National Center for Public Health and Pharmacy, H-1097 Budapest, Hungary.ORCID 0000-0003-0048-567X
Márta KnauszMicrobiology Laboratory, Aladar Petz University Teaching Hospital, H-1097 Győr, Hungary.
Béla GartnerCentral Department of Anesthesiology and Intensive Care, Aladar Petz University Teaching Hospital, H-1097 Győr, Hungary.
Ákos ReményiDepartment of Otorhinolaryngology, Head and Neck Surgery, North-Pest Central Hospital-Military Hospital, H-1097 Budapest, Hungary.
Edit BíróDepartment of Clinical Microbiology, North-Pest Central Hospital-Military Hospital, H-1097 Budapest, Hungary.
Erzsébet LétayDepartment of Clinical Microbiology, North-Pest Central Hospital-Military Hospital, H-1097 Budapest, Hungary.
László RókuszDepartment of Internal Medicine, North-Pest Central Hospital-Military Hospital, H-1097 Budapest, Hungary.
Szilárd TóthDepartment of Bacteriology, National Center for Public Health and Pharmacy, H-1097 Budapest, Hungary.
Bernadett PályiDepartment of National Biosafety Laboratory, National Center for Public Health and Pharmacy, H-1097 Budapest, Hungary.
Tünde MagDepartment of Bacteriology, National Center for Public Health and Pharmacy, H-1097 Budapest, Hungary.
Tímea ErdősiDepartment of Bacteriology, National Center for Public Health and Pharmacy, H-1097 Budapest, Hungary.
Nóra Deézsi-MagyarDepartment of National Biosafety Laboratory, National Center for Public Health and Pharmacy, H-1097 Budapest, Hungary.
Zsuzsanna MolnárCommunicable Diseases and Immunization Unit, National Center for Public Health and Pharmacy, H-1097 Budapest, Hungary.
Zoltán KisDepartment of National Biosafety Laboratory, National Center for Public Health and Pharmacy, H-1097 Budapest, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodsWe report two travel-associated melioidosis cases confirmed in Hungary between 2008 and 2024. Whole-genome sequencing (WGS), multilocus sequence typing (MLST), and core-genome MLST (cgMLST) were performed for molecular characterization. In parallel, a systematic review of travel-related melioidosis cases reported in Europe (1980-2025) was conducted according to PRISMA 2020 guidelines. Data were retrieved from PubMed, Scopus, Google Scholar, and the PubMLST database.

resultsIn silico MLST identified two distinct sequence types (STs): a novel ST1643, and ST1051, previously reported in Asia and Australia. Both isolates clustered within the Asian clade, confirming an imported origin. Virulence profiling revealed major determinants, including the Yersinia-like fimbriae (YLF) cluster, fhaB3, and ITS type C. The ST1643 isolate carried the

conclusionsThis study represents the first report of neuromelioidosis in Hungary, and the first global description of ST1643. Combined genomic and epidemiological data highlight the need for improved clinical awareness, genomic surveillance, and diagnostic preparedness in non-endemic regions, as global travel and climate change expand the distribution of melioidosis.

Indexed as

Burkholderia pseudomalleiMelioidosisTravel-Related IllnessFemaleGenome, BacterialGenomicsHumansHungaryMaleMiddle AgedMultilocus Sequence TypingPhylogenyTravelVirulence FactorsWhole Genome SequencingVirulence Factorsantimicrobial resistanceBurkholderia pseudomalleiclimate changecore genome MLST (cgMLST)emerging infectious diseasesEuropemelioidosisneuromelioidosisvirulence factorswhole genome sequencing (WGS)

Identifiers

PMID41305346
PMCPMC12654974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.